+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck. Results of a phase II Multicenter Study

Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck. Results of a phase II Multicenter Study

Cancer 79(7): 1394-1400

BACKGROUND: The combination of vinorelbine (VNR), cisplatin (CDDP), and 5-fluorouracil (5-FU) has previously been shown to be active in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCHNC). This Multicenter Phase II study was carried out with the aim of evaluating the effectiveness of this combination m patients with previously untreated, unresectable locally advanced SCHNC. METHODS: Sixty patients with previously untreated, unresectable SCHNC were treated with CDDP 80 mg/m-2 on Days 1, 5-FU 600 mg/ml as a 4-hour infusion on Days 2-5, and VNR 25 mg/m-2 iv bolus on Days 2 and B. There were 15 patients with laryngeal carcinoma, 19 patients with oropharyngeal carcinoma, 15 with carcinoma in the oral cavity, 5 with carcinoma in the hypopharynx, and 4 with carcinoma in the maxillary sinus. Most patients (78%) had Stage IV disease. After achievement of the best possible objective response, patients were subjected to definitive locoregional treatment, i.e., radiotherapy and/or surgery, as appropriate. RESULTS: All patients completed the induction chemotherapy. After a mean of 3.86 cycles per patient, the overall response rate was 88% (95% confidence interval (CI), 82-94%), with a complete response rate of 23% (95% CI, 14-26%). Complete responses were more frequently seen in patients with N0-1 disease than in those with N2-3 disease (P = 0.037). No other statistically significant correlation between type of response and extent of disease was noted. Toxicity consisted mainly of myelosuppression and gastrointestinal side effects. After definitive locoregional treatment, 58% of patients were clinically free of disease. These patients included those who had complete response after induction chemotherapy, 19 of 39 patients who had partial response, and 2 with stable disease. Median disease free survival was 16 months, and median overall survival was 23 months. CONCLUSIONS: The combination regimen of CDDP, 5-FU, and VNR was very active in previously untreated SCHNC. It was well tolerated in most cases, and neurotoxicity was not a major side effect. This regimen, which does not require hospitalization, should be compared with standard chemotherapy, such as the combination of CDDP and continuous-infusion 5-FU.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 009724608

Download citation: RISBibTeXText

PMID: 9083162

DOI: 10.1002/(sici)1097-0142(19970401)79:7<1394::aid-cncr17>3.0.co;2-v

Related references

Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. Journal of Neurology, Neurosurgery, and Psychiatry 61(4): 409-411, 1996

Treatment of recurrent and resistant CAPD peritonitis by temporary withdrawal of peritoneal dialysis without removal of the catheter. Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis 11: 176-178, 1995

Vinorelbine (Navelbine): a third-generation vinca alkaloid. Cancer Investigation 15(5): 475-490, 1997

A phase II study of tumour response rates and tumour HLA expression during treatment of metastatic malignant melanoma with low dose gamma-interferon. European Journal of Cancer 35(Suppl. 5): S17, 1999

A randomized phase III intergroup study of perioperative fluorouracil (5-FU) in patients with resectable colon cancer. Journal of Clinical Oncology 23(16_Suppl): 3552-3552, 2016

Neo-adjuvant androgen deprivation therapy prior to radiation therapy in localized prostate cancer The Victoria series. Clinical and Investigative Medicine 20(4 Suppl. ): S91, 1997

Neo-adjuvant and adjuvant treatment of locally invasive bladder cancer. Current Opinion in Urology 9(5): 419-424, 1999

Carboplatin alone or in combination with chlorambucil for advanced ovarian cancer. Gynecologic Oncology 32(1): 130, 1989

Disclosure-in the blink of an eye. Annals of Oncology 30(2): 169-170, 2019

Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-1882 boost versus no boost trial. 2011

Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics 56(4): 996-1004, 2003

Intensive combined modality therapy for limited-stage small-cell lung cancer. Journal of the National Cancer Institute 85(7): 559-566, 1993

Radiochemotherapy in the treatment of breast cancer. Clinical Oncology ) 21(7): 532-535, 2009

Cisplatin+Vinorelbine Treatment of Recurrent or Metastatic Salivary Gland Malignancies (RMSGM): A Final Report on 60 Cases. American Journal of Clinical Oncology 40(1): 86-90, 2017

Efficacy of bovine viral diarrhea virus vaccination to prevent reproductive disease: a meta-analysis. Theriogenology 83(3): 360-365.E1, 2015